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Control of membrane protein 
homeostasis by a chaperone‑like 
glial cell adhesion molecule 
at multiple subcellular locations
Haijin Xu5, Sandra Isenmann3,4, Tania López‑Hernández7,8, Raúl Estévez7,8, 
Gergely L. Lukacs5,6* & Pirjo M. Apaja1,2,3,4*
The significance of crosstalks among constituents of plasma membrane protein clusters/complexes in 
cellular proteostasis and protein quality control (PQC) remains incompletely understood. Examining 
the glial (enriched) cell adhesion molecule (CAM), we demonstrate its chaperone‑like role in the 
biosynthetic processing of the megalencephalic leukoencephalopathy with subcortical cyst 1 (MLC1)‑
heteromeric regulatory membrane protein complex, as well as the function of the GlialCAM/MLC1 
signalling complex. We show that in the absence of GlialCAM, newly synthesized MLC1 molecules 
remain unfolded and are susceptible to polyubiquitination‑dependent proteasomal degradation at 
the endoplasmic reticulum. At the plasma membrane, GlialCAM regulates the diffusional partitioning 
and endocytic dynamics of cluster members, including the ClC‑2 chloride channel and MLC1. Impaired 
folding and/or expression of GlialCAM or MLC1 in the presence of diseases causing mutations, as 
well as plasma membrane tethering compromise the functional expression of the cluster, leading 
to compromised endo‑lysosomal organellar identity. In addition, the enlarged endo‑lysosomal 
compartments display accelerated acidification, ubiquitinated cargo‑sorting and impaired endosomal 
recycling. Jointly, these observations indicate an essential and previously unrecognized role for 
CAM, where GliaCAM functions as a PQC factor for the MLC1 signalling complex biogenesis and 
possess a permissive role in the membrane dynamic and cargo sorting functions with implications in 
modulations of receptor signalling.
The crosstalk of membrane protein complexes and cluster members through homo- and heteromerization, 
protein–protein, protein-lipid interactions, post-translational modifications or cell–cell contacts can regulate 
complex functional  phenotypes1,2. Beyond subunit compositions, the biosynthetic secretion efficiency, the plasma 
membrane (PM) internalization, recycling and degradation kinetics can all influence oligomeric membrane 
protein steady-state level at the  PM3–6. Pending on the severity of the conformational defect, genetic mutations 
can partially or completely disrupt the endoplasmic reticulum (ER) folding/assembly of oligomeric PM proteins 
and reroute them for premature degradation by specialized organelle protein QC (PQC) mechanisms to elimi-
nate potentially toxic and aggregation-prone  proteins3,7,8. The significance of crosstalks among constituents of 
plasma membrane protein clusters/complexes in cellular proteostasis and PQC remains incompletely understood.
GlialCAM (HepaCAM1), like the Neural CAM (NCAM), vascular CAM or cluster of differentiation 22 and 48 
found in B- and T-cells9 mediating cell–cell or cell–matrix interactions and migration, are members of the immu-
noglobulin (Ig) family CAM. GlialCAM is widely expressed in human cells and abundant in the central nervous 
system glial cells. In particular, the astrocytic plasma membrane signalling cluster incorporates GlialCAM, the 
OPEN
1Department of Molecular and Biomedical Sciences, University of Adelaide, 5005 North Terrace, Adelaide, SA, 
Australia. 2College of Public Health and Medicine, Molecular Biosciences Theme, Flinders University, Bedford 
Park, SA 5042, Australia. 3Organelle Biology and Disease, South Australian Health and Medical Research 
Institute, Adelaide, SA 5000, Australia. 4EMBL Australia, Adelaide, SA 5000, Australia. 5Department of Physiology 
and Cell Information Systems, McGill University, 3655 Promenade Sir-William-Osler, Montreal, QC H3G 1Y6, 
Canada. 6Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada. 7Unitat de Fisiologia, 
Departament de Ciències Fisiològiques, IDIBELL-Institute of Neurosciences, Universitat de Barcelona, L’Hospitalet 
de Llobregat, Barcelona, Spain. 8Centro de Investigación en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, 
Spain. *email: gergely.lukacs@mcgill.ca; p.apaja@adelaide.edu.au
2
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18435  | https://doi.org/10.1038/s41598-021-97777-4
www.nature.com/scientificreports/
regulatory integral membrane protein MLC1 (megalencephalic leukoencephalopathy with subcortical cysts 
1), ClC-2 chloride and TRPV4 (cation) channels, receptors (EGF) and transporters  (Na+/K+-ATPase)10–14. 
This heteromeric cluster has been implicated in the regulation of astrocyte motility, cellular signalling and ion 
 homeostasis12,15–18. The expression defect in GlialCAM or MLC1 induces both intracellular and extracellular 
vacuolization in astrocytes and the  brain11,13,19,20. Overall, dysfunction of the cluster results in progressive brain 
defects, difficulties in movement, edema, epilepsy and  autism21–23.
We have an incomplete understanding of the underlying mechanistic cause of GlialCAM expression defect 
on the cluster. Intriguingly, loss of expression of MLC1 in the mouse brain causes GlialCAM mislocalization 
by unknown mechanisms, which in turn perturbs the subcellular distribution of the ClC-224. This implies that 
GliaCAM (and/or MLC1) modulates through less defined mechanisms direct protein and indirect functional 
interactions of the cluster members. In support, GlialCAM mutations disrupt MLC1 localization to astrocytic 
endfeet junctions of blood vessels and cell–cell  contacts11,25–27 and GlialCAM regulate ClC-2 chloride currents 
and the volume-regulated anion channel (VRAC/LRRC8) through kinase  signalling12,17. At least the cellular 
expression of ClC-2 is not dependent on  GlialCAM11 in contrast to MLC1, which follows that of GlialCAM. 
The mice lacking GlialCAM have severely and mutant GlialCAM mice moderately decreased cellular expression 
of  MLC124. This phenomenon could be partly attributed to the ability of GlialCAM to stabilize/localize ClC-2 
 channel12,18 and other members of the cluster with a presently poorly understood molecular mechanism.
Here we uncover that cell adhesion molecule GlialCAM is a PQC factor at multiple cellular locations. We 
show that GlialCAM expression suppresses the ubiquitin–proteasome system (UPS) mediated ER-associated 
degradation (ERAD) of MLC1, suggesting that it is required for the biosynthetic conformational stabilization 
of GlialCAM/MLC1 oligomer. The protection of MLC1 against ERAD was dependent on the cytosolic carboxy 
(C)-tail of GlialCAM, which was also required for its ER-to-PM targeting and tethering. At the PM, GlialCAM/
MLC1 forms a core for the adhesion phase separation module, regulating the endocytosis dynamics of the MLC1, 
GlialCAM and ClC2 in the cluster. Moreover, we find that lack of GlialCAM or MLC1 provokes fusion stress 
toward the endo-lysosomal compartment, contributing to the complex molecular brain pathogenesis associated 
with the cluster. Altogether, these studies highlight the unexpected importance of cell adhesion molecules in 
PQC for improving the proteostasis health of cells.
Results
Destabilization of MLC1 variant at the PM by diseases causing mutations. Megalencephalic leu-
koencephalopathy with subcortical cysts (MLC), the white matter disease of the brain, is caused by the expres-
sion defect of the MLC1 or GlialCAM gene  products11,26, predominantly confined to the plasma membrane. 
Molecular mechanisms of how GlialCAM and/or MLC1 expression defects manifest at the PM and subcellular 
level and modulate each other and the signalling cluster members implicated in a broad range of brain functions 
are far less understood. As the loss-of-expression phenotype of the mutant MLC1 signalling complex could 
be similar to a handful of mutant PM proteins attributed to ubiquitination- and ESCRT-dependent lysosomal 
targeting by the peripheral PQC activity in addition to ER  PQC3,6,28–30, we assessed first the impact of diseases 
associated mutations on the PM stabilities of MLC1  variants31.
To interrogate the PM-endosomal PQC contribution to the MLC1 loss-of-expression phenotype, we first 
determined the cellular and PM expression of the MLC1 variants (Fig. 1A,B) in relation to their PM stabili-
ties (Fig. 1C). The cellular expression was measured using Western blot analysis and the PM expression using 
extracellular HA-tag in MLC1 and cell surface (cs)-ELISA28. GlialCAM (GCAM) expression was adjusted by 
heterologous expression and siRNA depletion in Hela and astrocytic U251N cells with variable levels of endog-
enous GlialCAM (see Figs. 1A and 2A).
Both MLC1-P92S and -C326R mutations resulted in a profoundly reduced PM pool (~ 80–90%) (Fig. 1A) and 
cellular expression (~ 60–80%) (Fig. 1A,B) coinciding with their 3–4-fold increased PM clearance rate relative 
to the MLC1-wt (Fig. 1C). Both accelerated internalization (Fig. 1D) and defective recycling (Fig. 1E) relative to 
MLC1-wt account for the fast PM removal of mutants, mediated by specialized peripheral PQC  machineries32. 
In astrocytic U251N cells, the MLC1 mutant PM expression was reduced only by 30–70% as compared to HeLa 
cells, likely due to the higher endogenous GlialCAM expression in U251N cells (Fig. 1A,C, see also Fig. 2A). 
Importantly, MLC1-wt and P92S turnover were comparable at the PM between primary astrocytes, HeLa and 
astrocytic U251N cells (Fig. 1C), validating the cell line utility for our subsequent experiments.
Because certain conformationally defective mutant PM proteins could be rescued at low temperature 
(26 °C)5,28,29, we tested whether the PM expression, endosomal recycling and internalization rates of MLC1 
disease variants can be correlated to the topological localization of point-mutations (Fig. 1D,E and S1C). The 
low-temperature exposure resulted in a ~ 4-fold increase in the expression of MLC1-P92S and ~ 2-fold of C326R. 
Consistent with the conformational rescue of mutants, the MLC1-variants internalization rate was inhibited 
(Fig. 1D,E and Fig. S1C). As a correlate, thermal unfolding at 40 °C (2 h) further accelerated internalization rates 
of P92S and C326R by 2.5-fold, conceivably due to enhanced unfolding propensity of mutants at 40 °C following 
their temperature rescue (Fig. S1A).
Comparable PM expression defect was rendered by five missense mutations in transmembrane regions of 
MLC1, causing ~ 2–6-fold increased internalization rate and low-temperature folding rescue of the MLC1-wt 
(Fig. 1F, Fig. S1B,C). The only outlier was the N141K mutation in the second extracellular loop, displaying a wt-
like expression pattern, suggesting that some of the ~ 80 diseases causing MLC1  mutations31 may exhibit solely a 
functional defect without apparent conformational impairment. On the other hand, the ~ 3–4-fold reduced PM 
expression of MLC1-S246R and -S280L, could be attributed, at least partly, to their ~ 4-fold enhanced internaliza-
tion rate (Fig. 1F). In contrast, increased internalization (~ 2.5 fold) jointly with reduced ER processing efficiency 
can explain the ~ 6–10-fold loss of MLC1-G59E and V210D PM expression. These variants represent a class of 
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Figure 1.  Disease mutations destabilize the regulatory protein MLC1 in multiple cell types. (A,B) The 
correlation between the PM density and cellular total protein expression of MLC1 variants (wt, P92S, C326R) 
was measured at 37 °C and upon temperature rescue (26 °C, 24 h) in HeLa cells by cs-ELISA and Western blot 
analysis with densitometry. (C) The PM turnover of MLC1 variants was monitored in the primary astrocytes, 
HeLa, and astrocytic U251N cells using cs-ELISA. (D) Internalization rates of the MLC1 variants (wt, P92S, 
C326R) were determined using cs-ELISA. Internalization was initiated at 37 °C for 4 min after anti-HA binding 
at 4 °C in HeLa cells maintained at 37 °C or after following low-temperature rescue (26 °C, 24 h). Statistical 
significance in the internalization rate of non-rescued (37 °C) and low-temperature rescued (26 °C) MLC1 
variants are indicated on the right panel (U251N, 26 °C). (E) The endosomal recycling rates of MLC1 variants 
[wt, P92S (PS), C326R (CR)] were measured in HeLa and astrocytic U251N cells as described in “Materials 
and methods”. (F) Correlation between internalization rates (%/4 min) and relative cell surface densities (% of 
the wt) of eight MLC1 variants in HeLa cells at 37 °C (red squares) or after temperature folding rescue at 26 °C 
(24 h, blue squares). Data are from the Fig. S1B,C. Means ± SEM, n ≥ 3, *p < 0.05, **p < 0.01, ***p < 0.001.
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mutations that are recognized and eliminated by the combined activities of the ER and PM-endosomal PQC 
similar to hERG long QT heart syndrome PAS-domain  mutations6. Thus MLC1 disease-causing point mutations 
can confer folding and peripheral stability defects that additively diminish signalling cluster density at the PM.
Both GlialCAM and MLC1 modulate endosomal trafficking dynamics of the heteromer. Because 
molecular pathogenesis of GlialCAM mutations and their folding, targeting and/or oligomerization can impact 
the cellular fate of MLC1, we examined the impact of GlialCAM on the PM-endosomal stability of the MLC1. 
The ~ 3-fold lower endogenous GlialCAM expression of Hela than astrocytic U251N cells at the PM (Fig. 2A, 
see also Fig. S5E) fostered the modulation of GlialCAM levels in Hela. Cellular expression was measured using 
Western blot analysis and the PM expression using cs-ELISA. Overexpression of GlialCAM-Flag increased the 
cellular expression of MLC1-wt, -P92S and -C326R, but elevated only the MLC1-C326R PM density (Fig. 2B, 
Figure 2.  Early endocytic crosstalk of GlialCAM and MLC1 trafficking dynamics. (A) The relative PM density 
of endogenous GlialCAM (GCAM) was measured using cs-ELISA in indicated cell lines and expressed as a 
percentage normalized for cellular proteins. (B) GCAM effect to increase the cellular expression of MLC1 
variants (wt, P92S, C326R) was determined by immunoblotting (n = 8). (C) The PM stability of MLC1 variants 
was measured using cs-ELISA in the presence or absence of exogenous GCAM. (D) Exogenous GCAM 
enhances MLC1 variants [wt, P92S (PS), C326R (CR)] endosomal recycling, which was measured using 
cs-ELISA as described in “Materials and methods”. (E,F) The PM expression (E) and stability (F) of GCAM-wt 
and disease-causing GCAM-R92W were determined using cs-ELISA. GCAM-R92W (~  T1/2 < 1 h) was 
destabilized when compared to its wt counterpart (~  T1/2 2 h). (G) The impact of MLC1 variants [wt, P92S (PS), 
C326R (CR)] expression on the GCAM internalization was measured using cs-ELISA. (H) Comparison of the 
PM stability between overexpressed (tr) GCAM and endogenous GCAM (en) and upon coexpression of MLC1-
C326R was measured using cs-ELISA. Means ± SEM, n ≥ 3, *p < 0.05, **p < 0.01, ***p < 0.001.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18435  | https://doi.org/10.1038/s41598-021-97777-4
www.nature.com/scientificreports/
Fig. S2A, see also Fig. 3A). GlialCAM overexpression marginally altered the PM stability and internalization of 
MLC1 variants (Fig. 2C, Fig. S2B). This suggests that the endogenous adhesion molecule expression is sufficient 
to support MLC1-wt expression into the cluster. Nevertheless, GlialCAM accelerated the endosomal recycling 
of MLC1-P92S and C326R without impact on wt (Fig. 2D). Similarly, severe MLC1-C326R increased the PM 
density and endosomal recycling of GlialCAM (Fig. S2C,D).
The disease-causing R92W mutation in the N-terminal extracellular IgV-domain of  GlialCAM18 reduced the 
PM expression and stability of GlialCAM (Fig. 2E,F), reminiscent of the MLC1 mutants cellular phenotype. In 
contrast, the expression of MLC1-P92S or C326R significantly impeded the internalization rate of GlialCAM 
(Fig. 2G), which led to a marginal change in the PM stability of GlialCAM (Fig. 2H). Importantly, the PM sta-
bilities of endogenous and overexpressed GlialCAM were comparable (Fig. 2H). Jointly, these results suggest 
that GlialCAM cannot suppress the accelerated internalization of MLC1 disease variants and ~ 3-fold faster PM 
turnover persisted upon GlialCAM overexpression (Fig. 2C).
GlialCAM regulates the lateral PM mobility of MLC1. Coupled endosomal recycling dynamics 
between GlialCAM and MLC1 (Figs. 1E, 2D) implies that GlialCAM expression level may determine the mem-
brane phase-separation of the PM signalling cluster, acknowledged as a regulator of the transmembrane adhe-
Figure 3.  GlialCAM is a diffusional phase barrier for the MLC1 signalling cluster at the PM. (A) The indicated 
HA-MLC1 variants (wt, P92S (PS), C326R CR) interacting with GlialCAM (GCAM) were isolated from 
the PM using cs-IP with anti-GCAM Ab. The precipitates were analyzed using Western blot analysis with 
anti-HA or anti-Flag Abs. MLC1 was measured as fold change to wt (left panel) from co-IP-ed samples and the 
amount of GCAM pulldown was normalized to sample lacking MLC1 (right panel) in HeLa cells. (B) MLC1 
lateral diffusion at the PM was measured by FLIP. Indicated areas (white circles) were photobleached and the 
fluorescence loss was monitored in the adjacent red squares. The normalized intensity traces show fluorescence 
decay in cells +/− GCAM overexpression. (C,D) Summary of decay rate constants are expressed as 1/s for 
MLC1-wt (C) and P92S (D) in cells +/− GCAM overexpression. GCAM substantially restricts the diffusion of 
MLC1-wt at the free PM (PM) and cell–cell junctions (JC), in contrast to P92S showing restriction only at the 
free PM. Statistical analysis against mock (J-D) or wt in the junction (D) are indicated. Means ± SEM, n ≥ 3, 
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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sion, receptor signalling, and cell junction  formation1,33,34. To examine the physical proximity and expression 
level effect of GlialCAM on MLC1 at the PM, we performed cs-co-IP using an antibody against the extracellular 
epitope of GlialCAM. GlialCAM interacted with all MLC1 variants at the PM (Fig. 3A). The PM density of Gli-
alCAM was increased by ~ 2–7-fold upon MLC1-wt, P92S, or C326R expression, as compared to that without 
MLC1, in line with the PM density measurements of GlialCAM (Fig. 3A; lower right panel, Fig. S2C). Consistent 
with the ~ 3-fold enhanced recycling of GlialCAM in MLC1-C326R expressed cells (Fig. 2D), it provoked the 
largest GlialCAM increase in the IP.
In principle, GlialCAM could enhance extracellular, cell–cell junctional and/or cytoskeletal tethering resulting 
in reduced diffusional mobility of the cluster. To better understand the impact of GlialCAM expression on the 
MLC1 lateral diffusional mobility, we performed fluorescence loss in the photobleaching (FLIP) measurement 
on the extracellularly labelled PM resident MLC1 variants. GlialCAM overexpression (as in Fig. S2C) profoundly 
delayed the lateral mobility of MLC1 variants at non-junctional PM regions (Fig. 3B–D, Fig. S3A,B), suggest-
ing that an increase in GlialCAM intracellular interactions and homo-oligomerization is sufficient to enhance 
the tethering. Further, increased GlialCAM tethering by both intra- and extracellular interactions at junctional 
regions (JC in figures) was proportional to MLC1 variant folding state, where GlialCAM reduced mobility rates 
of MLC1-wt by ~ 47%, P92S ~ 60%, and C326R ~ 85% relative to endogenous GlialCAM control (Fig. 3C,D, 
Fig. S3C). This is likely due to cell junctions forming a stronger diffusional  barrier35 and MLC1 variants propor-
tional expression dependency of GlialCAM observed in Figs. 2 and 3A. Moreover, the lateral mobility rates of 
MLC1-wt, -P92S and -C326R were similar both in presence of endogenous or overexpressed GlialCAM at non-
junctional regions, implying that despite the attempts to maintain the cluster stoichiometry, the tethering itself 
is largely insensitive to the MLC1 conformational state (Fig. S3D). Thus, both GlialCAM and MLC1 expression 
levels can influence the overall tethering and mobility of the cluster at the PM.
GlialCAM/MLC1 regulates endosomal dynamics of the signalling cluster. The precise function of 
MLC1 remains enigmatic, but as a scaffolding molecule, it may exert its regulatory functions through multiple 
members of the GlialCAM/MLC1 signalling cluster. To gain more insights into the MLC1 heteromeric signal-
ling complex function, we established morphological and functional changes at the endo-lysosomal compart-
ment upon depletion of endogenous MLC1 or GlialCAM. Direct or indirect depletion of MLC1 by siMLC1 or 
siGlialCAM, respectively, resulted in a significantly enlarged endosomal compartment that could be, at least 
partly, attributed to impaired maintenance of the identity of endocytic organelles, reflected by the overlapping 
colocalization of markers of early endosomes (early endosomal antigen1 (EEA1)) with multivesicular bodies/
lysosomes  (Lamp2+) (Fig. 4A–C, Fig. S4A,B). High-content image analysis confirmed that the Pearson colocali-
zation coefficient of EEA1 with the lysosomal marker Lamp2 increased by more than ~ 2-fold from 0.27 ± 0.04 in 
non-targeted siRNA (siNT) exposed cells to 0.68 ± 0.004 or 0.61 ± 0.002, (n = 3; ~ 300 cells/repeat) in MLC1- or 
GlialCAM-depleted cells, respectively (Fig. 4B). This was accompanied by a similar reduction in the number of 
lysosomes by ~ 43% from 154 ± /12 in siNT to ~ 68 ± 16 in siMLC1/GCAM cells (Fig. S4C) exclusively stained 
for Lamp2. Concomitantly, the mean diameter of the siNT treated lysosomes (0.58 ± 0.001 µm) increased ~ 56% 
when MLC1 (~ 1.02 ± 0.003 µm) and GlialCAM (~ 1.05 ± 0.003 µm) was depleted (Fig. 4C). Jointly, these obser-
vations suggest that MLC1 haploinsufficiency severely perturbs the identity of endo-lysosomal organelles, indic-
ative of their homeostatic/proteostatic  stress36.
Next, the functional consequences of the endo-lysosomal homeostatic perturbations were examined by moni-
toring compartment-specific regulation of endo-lysosomal pH. The gradual acidification is a hallmark of the 
endo-lysosomal compartment, starting at near-neutral pH of endocytic vesicles and progressing via early- (pH 
6–6.4) and late-endosomes/MVB (pH 5.5–6.0) to the highly acidic lysosomes (pH < 5.5)5,28,37–39. To determine 
whether the enlarged early-late-endosomal compartment is connected to altered acidification, we used pH-
sensitive single vesicle fluorescence microscopic analysis in live  cells5,28,37,38. Following the fluid-phase label-
ling of the endosomal compartments with the pH-sensitive dextran with a 5 min pulse, the luminal pH of the 
Figure 4.  A misaligned GlialCAM signalling cluster causes late endosomal enlargement and increases the early 
endosomal resident time of ClC-2. (A) MLC1 expression effect on late endosomes-lysosomes was monitored 
using siMLC1 and siNT (non-targeted) mediated depletion in astrocytic U251N cells. Lamp2 marker is for 
lysosomes and EEA1 for early endosomes. Bar: 5 µm. (B) High-content image analysis of immunostaining and 
treatments in panel (A). EAA1/Lamp2 + colocalization was analyzed using Pearson’s correlation coefficient. siNT 
was used as a control in comparison to siMLC1 and siGCAM depleted U251N cells (~ 300/repeat, n = 3). (C) 
As in (B), but the mean diameter of individual  Lamp2+ lysosomes was measured (n = 21,656–47,877/repeat of 
lysosomes). (D) Representative histograms of the endo-lysosomal pathway vesicular pH (pHv) measurement 
in siNT, siMLC1 and siGCAM astrocytic U251N cells. Live cells were loaded with pH-sensitive dextran for 
5 min and chased for 20 min before single vesicle analysis. (E) Mean vesicular pH (pHv) of cells in (D) chased 
for indicated times. Characteristic endosomal pH in control siNT cells is indicated. (F) Mean vesicular pH 
(pHv) of cells in (D) labelled for transferrin receptor (TfR) containing recycling or misfolded (CD4tl-L57C) and 
constitutively ubiquitinated (CD4tl-Ub) model cargo endosomes. (G) Strongly recycling transferrin receptor 
(TfR) amount at the PM was measured using cs-ELISA. (H) Immunofluorescence of internalized ClC2 and 
colocalization with EEA1 in cells +/− GCAM and +/− MLC1 overexpression in HeLa cells. Bar: 5 µm. (I) The 
impact of GCAM-wt, GCAM-R92W, and MLC1 expression on chloride channel HA-ClC-2 internalization 
was measured for 5 min at 37 °C using cs-ELISA in HeLa cells. (J) Manders’ overlap coefficient of ClC2 with 
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endocytic compartment was measured as a function of chase time (2–60 min, 37 °C)37,38. Both GlialCAM- and 
MLC1-depletion resulted in the accelerated acidification of the dextran-labelled compartment(s) after 20 min 
chase, likely due to the increased propensity of the early/late endosomes and lysosomal fusion or impeded fluid-
phase exocytosis (Fig. 4D,E).
We also examined the intracellular itinerary of several cargo molecules with distinct sorting signals. The pH 
of TfR receptor-labelled recycling endosomes was decreased in MLC1 (5.97 ± 0.03) and GlialCAM (5.82 ± 0.08) 
depleted cells compared to non-targeted siRNA treated cells (siNT; pH 6.26 ± 0.07) (Fig. 4F). Both the misfolded 
chimeric transmembrane model protein (CD4tl-L57C) and the constitutively ubiquitinated (CD4tl-Ub) model 
cargoes, which undergo ubiquitin- and ESCRT-mediated cargo sorting toward  lysosomes28, were confined to 
significantly lower pH compartment in MLC1- or GlialCAM-depleted than in control cells after 1 h chase indi-
cating accelerated lysosomal sorting and/or fusion and/or hyper-acidification of late-endosomes (Fig. 4F). While 
the precise mechanism of the altered organellar pH regulation remains to be elucidated, these unexpected results 
suggest a fundamentally altered pH homeostasis and consequential cargo sorting recycling/kinetics along with 
the endo-lysosomal compartments. Confirming this, the amount of TfR recycling was decreased by ~ 35% at the 
PM (Fig. 4G), similarly to the uptake and recycling of the horseradish peroxidase (HRP), a fluid-phase marker, 
by > 30% (Fig. S4D) and ~ 10%, respectively (Fig. S4E). Importantly, MLC1-S280L was not able to rescue HRP 
trafficking defects (Fig. S4D,E). These results show that despite enlargement, the endo-lysosomal compartment 
acidification is preserved, but the loss of compartmentalization severely perturbs endosomal cargo sorting and 
recycling, an indication of the endosomal compartment stress.
Permissive role of GlialCAM/MLC1 on the regulation of ClC‑2 at the PM‑endosomes. As the 
expression of GlialCAM and MLC mutually influences their PM partitioning, tethering (Fig. 3, Fig. S3), and 
endocytosis dynamics (Fig. 2, Fig. S2), we posit that GlialCAM may form a bridge between ClC-2 to MLC1 
in the ternary complex and a similar paradigm of membrane partitioning may prevail for ClC-2. To examine 
this scenario, we determined the ClC-2 channel PM density and residence time in early endosomes in cells 
depleted for GlialCAM or expressing GlialCAM disease mutant. Immunofluorescence microscopy showed that 
ClC-2 clustered to structures outside the ER in cells lacking MLC1, especially when GlialCAM was depleted 
or mutated (R92W) (Fig. 4H, Fig. S4F,G). Cs-ELISA and colocalization assays uncovered that in the absence 
of MLC1, GlialCAM-wt and -R92W significantly increased internalization and colocalization of ClC-2 with 
EEA + early endosomes (Fig. 4H–J). In contrast, the lack of both GlialCAM and impeded MLC1 internaliza-
tion and promoted the accumulation of isolated clusters of ClC2 at the PM and, possibly at the sub-plasma 
membrane regions in the form of budding endocytic vesicles (Fig.  4H, see -GCAM/-MLC). Whereas Glial-
CAM-R92W rendered faster internalization of the ClC2 than GlialCAM-wt in the presence of MLC1 (Fig. 4J), 
we could not detect a significant difference in endosomal localization (Fig. 4I). Taken together, the analysis of 
GlialCAM provided insights into the compositional partitioning and its effect on the functionality of the PM-
endosomal compartment.
GlialCAM stabilizes the MLC1‑complex at the ER. We have shown that GlialCAM ablation in pri-
mary astrocytes or knockout mice abolished the junctional and cell surface localization, and reduced the total 
expression of  MLC111,24,40. While this phenotype is consistent with GlialCAM regulating the targeting of MLC1, 
the underlying mechanism of the severe expression defect of MLC1 caused by the loss-of-GlialCAM expression 
remains largely speculative. Here we showed that GlialCAM overexpression significantly elevated the steady-
state cellular expression of MLC1 without influencing its peripheral metabolic turnover (Fig. 2B). We envision 
three possible mechanisms of actions of GlialCAM on MLC1 biogenesis. (i, ii) GlialCAM association may mask 
the ER retention signal (i) or expose ER export signals (ii) identified in the MLC1 cytosolic  segments10, or (iii) 
GlialCAM binding allosterically stabilizes and/or promote the folding of the MLC1 in the heteromeric complex. 
Notably, the efficacies of these functional modalities of GlialCAM may also be influenced by MLC1 mutation-
induced conformational changes.
First, we established the subcellular distribution and turnover of MLC1-HA variants in the calreticulin-
labelled ER by using the immunofluorescence co-localization technique. MLC1-wt was primarily confined to the 
PM adhesion processes in astrocytic U251N cells and was absent from the ER (Fig. 5A, Fig. S5A). In contrast, the 
mild P92S and the severe C326R mutation displayed a partial and near-complete colocalization, respectively, with 
calreticulin (Fig. 5A, Fig. S5A). The cellular turnover of MLC1 variants was monitored using immunoblotting 
after translational termination with cycloheximide (CHX). MLC1-wt exhibited biphasic degradation kinetics 
with fast  (T1/2 < 2 h) and slower turnover pools  (T1/2 > 2 h) (Fig. 5B). In contrast, MLC1 mutants, predominantly 
confined to the ER, displayed a monophasic decay with  T1/2 of ~ 1 h for S280L, ~ 0.5 h for C326R and ~ 1.5 h for 
P92S (Fig. 5B).
We postulated that a fastly turning over pool of MLC1 represents the proteolytic degradation of newly synthe-
sized MLC1 nascent chains or conformationally defective heteromeric complexes, and are therefore subjected to 
recognition and elimination by the ubiquitin–proteasome system, a constituent of the ER  PQC8. Supporting this 
hypothesis, the CHX-induced disappearance of mutants was delayed with the proteasome inhibitor Bortezomib 
(Fig. 5C, Fig. S5C). Conversely, MLC1-wt and the mild disease P92S mutation exhibited slower cellular turnover 
that could be attributed to more efficient conformational maturation and/or cluster assembly in the presence of 
endogenous GlialCAM. The steady-state accumulation of these variants was promoted by their slower degrada-
tion in post-Golgi compartments (Fig. 5B,C, Fig. S5B).
The ER confinement with efficient and near-complete clearance of the MLC1-S280L and -C326R cellular pools 
argue against the possibility that GlialCAM could selectively mask an ER-export motif(s) or induce the exposure 
of ER-retention signal(s) in these MLC1 variants. Both scenarios would manifest accumulation in the ER of the 
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transport-incompetent but natively folded mutants as described for other membrane  proteins8,39, however, this 
was not the case for MLC1 (Fig. 5D).
To directly assess the role of GlialCAM in the MLC1-wt biogenesis, a short hairpin (sh)RNA depletion was 
established, a prerequisite to generate loss-of-function and gain-of-function phenotype for GlialCAM (Fig. 5D, 
Fig. S5D–F). Depletion of GlialCAM further accelerated the turnover of MLC1-wt and P92S pools to  T1/2 < 0.5 h 
(Fig. 5D). Conversely, GlialCAM overexpression delayed both the fast phase of MLC1-wt turnover to  T1/2 ~ 2 h 
and the second slower to ~ 6 h (Fig. 5D). A similar trend was observed for P92S turnover, but without a significant 
impact on C326R, displaying the fastest metabolic turnover in the ER (Fig. 5D, Fig. S5D). Part of the C326R 
and to a lesser extend of P92S turnover was also catalyzed by lysosomal degradation since inhibition of the 
autophagosomal-lysosomal proteolysis of lysosomal cathepsins with leupeptin (L) or formation of autophago-
somes with 3-methyladenine (A) delayed the mutants metabolic turnover (Fig. S4A). Jointly, these observations 
support our conclusion that GlialCAM is not merely a permissive factor for MLC1 secretion from the ER but 
it is essential for the conformational-dependent metabolic stabilization of both the wt and some of the mutant 
MLC1 variants as well at the ER.
Figure 5.  GlialCAM increases the ER stability of MLC1. (A) Immunofluorescence co-localization of MLC1 
variants with the ER marker calreticulin. MLC1 variants were detected with indirect immunostaining using 
an anti-HA primary antibody in astrocytic U251N. Notably, the MLC1-wt displays marginal accumulation 
in the ER. Bar 5 µm. (B) Cellular turnover of MLC1 variants was monitored upon translational inhibition 
with cycloheximide (CHX) for 1–6 h. Western blot analysis revealed the fast (gray area) ER-clearance and the 
slow post-ER pools of MLC1-wt during CHX-chase in comparison to only the fast turnover pools of disease 
associated mutants. (C) Immunostaining of MLC1 variants before and after CHX chase (1–2 h) in the absence 
or presence of proteasomal inhibition (B) with Bortezomid (1 µM) during the CHX treatment. MLC1 was 
detected with an anti-HA antibody and ERp57 was used as an ER marker. Bar 5 µm. (D) The GCAM effect on 
the total cellular turnover of MLC1 variants was measured by immunoblotting during CHX-chase in HeLa 
cells. GCAM was overexpressed or depleted ~ 60% with a short hairpin (sh). Non-target shRNA (shNT) was as a 
control. Non-tr; non-transfected, lys; lysate. Means ± SEM, n ≥ 3.
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GlialCAM promotes MLC1 conformational maturation at the ER. To further evaluate whether Gli-
alCAM is an essential or only facultative folding stabilizer of MLC1, we progressively downregulated GlialCAM 
using different amounts of siRNAs (Fig. S5E) and in parallel monitored the expression of both MLC1-wt and 
Figure 6.  The cell adhesion protein, GlialCAM, protects MLC1 against ubiquitination and degradation at 
the ER. (A) The correlation of the PM expression between endogenous GlialCAM (GCAM) and exogenous 
MLC1-wt was measured using cs-ELISA in HeLa cells and expressed as a percentage of mock-treated MLC1-wt 
cells. The GCAM downregulation efficiency was altered by using different amounts of siGCAM. (B) Western 
blot analysis of GCAM downregulation on the cellular expression of MLC1 variants was determined after 
depleting ~ 60% of GCAM with short hairpin (sh)RNA or shNT (non-targeted). Total MLC1 expression 
was quantified against the loading control  Na+–K+-ATPase  (Na+K+). (C) GlialCAM overexpression protects 
MLC1-C326R against rapid ER elimination. Immunoblot analysis of MLC1 and GCAM expression levels was 
carried out after 20 h BFA (5 µg/ml) or mock-treated HeLa cells with or without GlialCAM overexpression. 
(D) The ER-confined MLC1-wt and C326R degradation were monitored in fully GCAM (sh/si) depleted or 
control (NT) HeLa cells. The ER-to-Golgi transport was inhibited with BFA (5 µg/ml) for 20 h, and the ER was 
cleared using CHX-chase for 30 min with or without proteasomal inhibition (Bortezomib, 1 µM). The absence 
of complex glycosylation in the hERG channel confirmed BFA efficacy by disrupting ER-to-Golgi transport. 
(E) The influence of GCAM expression on the PM amount of MLC1-wt was measured using cs-ELISA. 
Proteasomal inhibition (Bortezomib, 2 h) was unable to rescue the PM expression of MLC1 when GCAM was 
partially depleted as in panel Fig. 4B. (F) GCAM overexpression effect on the MLC1 ubiquitination at the ER 
was measured in HeLa cells treated with BFA for 20 h and +/− GCAM. MLC1-wt or C326R were IPed with 
anti-HA under denaturing conditions. The ubiquitin signal was normalized to MLC1 expression in the IP (left 
panel). GCAM overexpression decreases the normalized MLC1-C326R ubiquitination by ~ 5-fold (right panel). 
(G) The overexpression effect of GCAM on MLC1-wt ubiquitination at the ER was measured in cells treated 
with BFA for 20 h. GCAM was depleted (si/sh) or cells treated with non-target (NT) and proteasomal inhibitor 
(Bortezomib, 2 h). MLC1-wt was immunoprecipitated with anti-HA under denaturing conditions to measure 
direct ubiquitination. Means ± SEM, n ≥ 3. ****p < 0.0001.
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GlialCAM at the PM. Our results unravelled a linear correlation between the GlialCAM and MLC1 expression 
at the PM (Fig. 6A). Notably, near-complete depletion of GlialCAM reduced the PM expression of MLC1-wt 
by > 95% (Fig.  6A). Western blot analysis showed that > 80% downregulation in endogenous GlialCAM elic-
ited > 90% loss of cellular expression of disease MLC1 variants (except the S246R) (Fig. 6B). Thus, GlialCAM is 
indispensable for folding/conformational stabilization and escape of newly synthesized MLC1-wt molecules in 
the heteromeric signalling complex from the ER QC.
To reinforce our conformational stabilization model, we determined the fate of newly synthesized MLC1 
molecules in the ER after inhibition of the ER-to-Golgi vesicular transport with Brefeldin A (BFA). It is worthy 
of notice that natively folded membrane proteins are resistant to the ER QC and their stability in the ER and post-
ER compartments are  comparable41. GlialCAM overexpression was increased the accumulation of ER-retained 
MLC1-C326R by ~ 3-fold, conceivably by partially suppressing its conformational defect (Fig. 6C). In accordance, 
depletion of the endogenous GlialCAM prevented the ER accumulation of both MLC1-wt and C326R, which 
was reversed by proteasomal inhibition (Fig. 6D). Importantly, the PM expression of MLC1-wt was enhanced 
by proteasomal inhibition only when GlialCAM was expressed, but not in its absence (Fig. 6E). Jointly, these 
results provide support for our model that GlialCAM loss-of-function/expression severely compromises the 
conformational maturation of MLC1 variants in the heteromeric complex, which becomes susceptible to the ER 
retrotranslocation and proteasome-dependent degradation. Consistently, dominant GlialCAM mutations also 
cause a defect in MLC1  expression20, as observed in GlialCAM-knockdown  mice24.
GlialCAM protects MLC1 from ubiquitination in the ER. Ubiquitination represents and a well-
established targeting signal of conformationally defective membrane proteins for the ERAD by the  UPS42. The 
effect of GlialCAM on the ER-trapped MLC1 ubiquitination levels was determined using denaturing immu-
noprecipitation (IP) to preclude isolation of interacting ubiquitinated proteins followed by anti-ubiquitin (Ub) 
Western blot analysis. GlialCAM overexpression reduced ~ 5-fold both MLC1-wt and C326R polyubiquitination 
(Fig. 6F). Under the same condition, GlialCAM was moderately ubiquitinated (Fig. S6). Importantly, depletion 
of GlialCAM led to a profound increase in polyubiquitination of MLC-wt at a comparable to that observed 
upon proteasomal inhibition (Fig. 6G). This gives further credence to our conformational model showing that 
GlialCAM interacts at the ER with both unassembled and/or folding intermediates of MLC1-wt and misfolded 
C326R. Therefore, we suggest that the chaperone-like function of GlialCAM can limit the ERAD susceptibility 
of MLC1 by shifting the hetero-oligomeric MLC1 complex toward its native-like conformation.
The C‑terminal tail of GlialCAM rescues the MLC1 expression defect. To identify the GlialCAM 
domain responsible for interaction with MLC1 in the ER, we deleted the N-terminus (ΔN) and C-terminus 
(ΔC) tails, as well as inserted two disease-causing point-mutations (R92Q, R92W) into the N-terminal domain 
of  GlialCAM18, exposed to the ER-lumen, characteristic for a type I transmembrane  proteins18. GlialCAM vari-
ants were expressed in cells depleted for endogenous GlialCAM and expression was confirmed by Western blot 
analysis and cs-ELISA (Fig. 7A and Fig. S7A). GlialCAM variants, except GlialCAM-ΔC, supported the PM 
expression of MLC1-wt (Fig. 7A) indicating that the C-tail of GliaCAM is sufficient to rescue MLC1 folding/
trafficking in trans. Expression of the GlialCAM C-tail in the CD4t-GCAMCt chimera was able to restore the PM 
expression of the MLC1-wt, in contrast to the full-length CD4 or the truncated CD4, lacking its C-terminal tail 
(CD4t)28,43 (Fig. 7B). CD4t-GCAMCt overexpression also delayed the ER clearance of MLC1-wt in the presence 
of BFA (Fig. 7C). Confirming these results, recombinant GST-GlialCAMCt was able to capture MLC1-wt, P92S 
and C326R in a pull-down assay (Fig. 7D).
To examine the chaperone-like consequences of GlialCAM structural variations outside the ER, we deter-
mined the morphology of the endo-lysosomal compartment as in Fig. 4A and S4A,B. Importantly, expression 
of GlialCAM-ΔC in GlialCAM-depleted cells induced enlarged accumulative Lamp + lysosomal compartment 
and was not unable to rescue the endosomal compartment homeostasis/proteostasis stress (Fig. 7E, Fig. S7B). 
These data revealed that the C-terminal cytosolic tail of GlialCAM can promote conformational maturation and 
assembly of the signalling complex by rendering MLC1 resistant to ERAD.
Finally, to directly address the GlialCAM impact on the stability of the newly synthesized MLC1 molecules, 
we performed metabolic pulse labelling with  [35S]-methionine and  [35S]-cysteine. Overexpression of GlialCAM 
increased the biogenesis of MLC1-wt by > 2-fold during a short 20 min pulse labelling (Fig. 7F). This could 
attribute to both fast co- and posttranslational folding and delayed ER degradation of the MLC1-wt, considering 
that one MLC1 chain (377 amino acids) translation is completed in one min (~ 6 amino acids/s)44.
To more accurately estimate the conformational maturation efficiency of MLC1 and minimize the influence of 
ER degradation of GlialCAM on MLC1, we improve the signal intensity by implementing a longer pulse labelling 
(1 h), followed by a 3 h chase. This approach encompasses the labelling of a larger cohort of newly synthesized 
proteins, as well as monitoring the combined effect of three consecutive ER processes: MLC1 degradation, fold-
ing, and ER-exit. It also serves as an indicator to membrane protein processing along the biosynthetic pathway 
because MLC1 lacks N-glycosylation typically used to detect the processing-dependent mobility shifts of secreted 
 polypeptides45,46. The increased radioactive 35Met and 35Cys incorporation into the wt and mutant MLC1 after 
3 h chase indicates that GlialCAM overexpression enhanced the accumulation of the MLC1 variants in post-
ER compartments (Fig. 7F,G, Fig. S7C) providing direct evidence of improved conformational maturation and 
diminished ER degradation of MLC1 molecules.
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Figure 7.  GlialCAM is a chaperone-like folding assistant at the ER to enhance MLC1 biosynthetic secretion. 
(A) Structural requirements of GlialCAM (GCAM) for MLC1 trafficking to the PM. The PM density of MLC1 
was measured using cs-ELISA in GCAM-depleted (si/sh) HeLa cells and expressing C- or N-terminally 
truncated GCAM-Flag variants as indicated. Western blot analysis is shown in lower panels. The C-terminal 
tail was minimally required to enable the PM targeting of MLC1. GCAM-R92Q or W are MLC disease-causing 
mutations. (B) The effect of the C-terminal tail of GCAM in trans on the PM expression of MLC1 was measured 
using cs-ELISA. Cells were depleted for GCAM (si/sh) and coexpressed with the C-terminal tail of GCAM fused 
to the truncated CD4, lacking its cytoplasmic tail (CD4t-GCAMCt). CD4t and CD4 were used as controls. (C) 
Western blot analysis of  GCAMCt effect on the ER-retained MLC1 in the presence of BFA was performed as in 
panel (D), except using CD4t-GCAMCt coexpression and CD4t as a control. (D) Pulldown of MLC1 variants 
from cell lysates with the GST or GST fusion protein, containing the  GCAMCt (GST-GCAMCt). (E) The effect 
of GCAM truncation on the endo-lysosomal pathway morphology was monitored in GCAM depleted (si/sh) 
astrocytic U251N cells. GCAM expression was detected with anti-GCAM and lysosomes with anti-Lamp1 Ab. 
Arrow points to enlarged Lamp1 + lysosomes. Bar 5 µm. (F) Phosphorimage analysis of metabolic pulse labelled 
(20 min, 37 °C) MLC1 with  [35S] methionine/cysteine in +/− of GlialCAM overexpressing cells. (G) GlialCAM 
effect on the maturation of MLC1. Metabolic pulse-chase experiments as in panel (E), but using 1 h pulse-
labelling at 26 °C and 3 h chase at 37 °C to allow the complete degradation of the ER-resident labelled MLC1 
pool. Means ± SEM, n ≥ 3. *p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
Here we found that GlialCAM acts as a PQC factor both at the ER, as well as along the endocytic compartments 
(Fig. 8). In the ER, GlialCAM exhibits an obligatory chaperone-like activity toward the newly synthesized MLC1 
nascent chains by aiding their conformational maturation/stabilization and protecting both the wt and mutant 
MLC1s against polyubiquitination- and proteasomal-dependent ERAD. Our biochemical turnover studies rule 
out the possibility that GlialCAM/MLC1 heteromerization acts on the MLC1 biogenesis by masking the ER-
retention motif and/or exposing the ER-export signal in MLC1. Jointly, these results provide a mechanistic 
framework for the absolute dependency of the MLC1 heteromeric signalling cluster on GlialCAM expression. The 
indispensable role of GlialCAM in the biogenesis of the MLC1 signalling cluster with its endosomal homeostatic 
function offers a plausible explanation for the variety of brain dysfunctions associated with this  cluster15–17,47–50 
and highlights the broader role of CAMs in maintaining cellular health.
Distinct molecular events have been identified for the mechanism and function of CAMs heterooligomeriza-
tion. The ER exit of the multimeric neuronal synaptic N-Methyl-D-aspartic/aspartate receptor (NMDA) requires 
two NCAM-subunits to mask its ER retention signal and enhance the PM delivery of the  NMDA51,52. NCAM is 
also known to modulate the synaptic trafficking of the NMDA  receptor51,52. The Ig-domain type CAMs neuro-
plastin and basigin interact with the PM  Ca2+-ATPases (PMCA) 1–4 subunits and facilitate the PMCA-complex 
delivery to the cell surface independently of their Ig domains. At the PM, the interaction modulates both the 
 Ca2+ transport activity and  Ca2+ binding-site exposure to the  cytoplasm53. Based on earlier data, we can rule out 
the transcriptional regulation of MLC1 by  GlialCAM12.
Our findings provide direct evidence in support of the chaperone-like folding assistance of CAM for MLC1 
variants and be a QC-factor for the MLC1 signalling complex. The cytosolic C-terminal tail of GlialCAM pro-
motes the conformational maturation/assembly of the MLC1 in the ER. Whether the association of GlialCAM 
with MLC1 takes place after their nascent chains synthesis or initiated cotranslationally as demonstrated for 
certain oligomeric  proteins54, remains to be tested.
The data that GlialCAM disease R92W mutation in the N-terminal IgV adhesion domain has reduced PM sta-
bility agree with a requirement of extracellular adhesion of GlialCAM to position MLC1 at the  PM27,55. GlialCAM 
partitions the PM signalling cluster and the misaligned transmembrane phase separation seems to contribute to 
interfered interactions of signalling complexes in GlialCAM expressing cells both in trans and  cis55. Notably, the 
neuroplastin CAMs have a similar anchoring role for the GluR1,  GABAA, and monocarboxylate  transporters56,57. 
Our model suggests that GlialCAM regulates the endocytosis dynamics of the MLC1 cluster members consistent 
Figure 8.  Cell adhesion molecule (CAM) can act as a chaperone-like molecule to regulate proteostasis and 
endocytosis. GlialCAM functions as a chaperone-like molecule in the ER by ensuring the conformational 
maturation of the regulatory membrane protein MLC1 and consequently protects MLC1 against ERAD. As 
a result, GlialCAM enhances the ER-exit, the PM targeting and the tethering of MLC1 variants. At the PM, 
GlialCAM regulates the diffusional phase separation of the PM proximity adhesion module, which links 
GlialCAM to early endocytosis dynamics of at least cluster members MLC1 and chloride channel ClC-2. 
Misaligned adhesion cluster, probably partly due to the inappropriate stoichiometry upon MLC1 or GlialCAM 
misfolding/mislocation or lack of expression leads to loss of proteostasis health at the late endosomal/lysosomal 
compartment. Hence, CAM can shape the dynamics of membrane protein folding QC, the diffusional phase 
separation at the PM and endocytosis of the proximity adhesion cluster.
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with its influence on the transmembrane  signalling1, the formation of tight junctions, and cell  polarity33. Here, it 
modulated the PM-endosomal resident time of MLC1 and ClC-2, explaining the GlialCAM-mediated regulation 
of the ClC-2 current  density12.
Intriguingly, the primary expression defect of MLC1 mutants (e.g. P92S or S280L) or as a consequence of 
GlialCAM loss-of-expression, here we report an accelerated drop in the vesicular pH along with the endo-
lysosomal compartments (Fig. 4D,E), suggesting that the vacuolar  (H+) V-ATPase responsible for acidification is 
incorporated and functional. The endosomal compartment enlargement is likely due to an increased propensity 
of homo- and heterotypic fusion of endosomes as suggested by the redistribution of the biochemical hallmarks 
of endo-lysosomal organelles (Fig. 4A–C). This could be, at least partly, due to the elevated cytoplasmic  Ca2+ 
concentration, which is accompanied by augmented lysosomal exocytosis and activation of a proteotoxicity-
dependent PQC  mechanism32. Consistent with the critical role of adhesion in proteostasis health, a recent study 
showed that cell–cell adhesion enhances cellular resistance against  proteotoxicity58. The augmented fusion and/
or reduced fission propensities of endo-lysosomes with accelerated acidification of endocytic compartments may 
have far-reaching consequences in a variety of signalling processes involved in brain homeostasis.
By extrapolation, our results also suggest possible alterations in several ubiquitinated receptors and PM pro-
tein trafficking, as well as the downstream cellular signalling connected to the MLC1 signalling cluster. Substantial 
changes were observed in the sorting kinetics of ubiquitinated and recycled transmembrane cargoes and the 
fluid-phase markers in cells expressing mutant MLC1 (Fig. 4). While the precise molecular explanation requires 
further research, the observed phenomena could be, at least partly, explained by perturbations of the vesicular 
pH regulation via modulated counterion conductances and/or subunit compositional changes of the V-ATPase, 
as well as the rearrangement of the actin cytoskeleton as observed in MLC1 haploinsufficient  cells15,16. Based on 
these considerations we propose that the MLC1-heteromer formation plays a critical role in maintaining the 
endo-lysosomal compartment morphological and functional homeostasis and identities.
Materials and methods
Cell culture and transfection. Parental or inducible Lenti-X Tet-On5 HeLa and U251N cells with and 
without 2HA-MLC1 expression were used in experiments and cultured under standard conditions. Lentivirus 
production, transduction, doxycycline  induction5 and depletion of endogenous GlialCAM expression were done 
as described  before11. Transfection of plasmid DNA was performed using Lipofectamine 2000 (Thermo Fisher 
Scientific) and siRNA using RNAiMAX or Oligofectamine transfection reagent (Thermo Fisher Scientific). Pri-
mary rat astrocytes were isolated and cultures and transfected as described  before11.
Live‑cell surface ELISA. The membrane protein expression, turnover and recycling were measured using 
the PM epitope labelling and cs-ELISA in live cells for kinetic  studies5,12,28,59. Internalization was measured for 
5 min, recycling 20 min and stability for indicated times at 37 °C. Transferrin-HRP or HRP-conjugated second-
ary antibody (Ab) was measured either by luminescence using HRP-Substrate (SuperSignal West Pico, Thermo 
Fisher Scientific) or Ampilite (ATT Bioquest, CA, USA) or Amplex Red assay (Thermo Fisher Scientific).
HRP‑uptake and recycling assay. The enzyme horseradish peroxidase (HRP; Thermo Fisher Scientific) 
was loaded in 0.1 mg/ml for indicated times into cells at 37 °C. Cells were lysate and HRP signal was detected 
using Ampilite (ATT Bioquest, CA, USA). The received signal was normalized to mg of protein in each sample. 
For measuring recycling capacity, HRP was loaded for 10 min and allowed to recycle for 20 min at 37 °C before 
measurement from the medium.
Immunoprecipitation and protein analyses. In total cell IP, the Ab was added directly to cell lysates. 
Selective isolation of GlialCAM from the PM was achieved by cs-IP using anti-GlialCAM Ab (1:2000, R&D Sys-
tems, MN, USA). Ab was bound on ice to the live cell PM for 45 min, after which the unbound Ab was washed 
off. Cells were lysed in Triton X-100 lysis buffer (1% Triton X-100, 25 mM Tris–Cl, 150 mM NaCl, pH 8.0, 10 μM 
MG132 containing 20 μM PR-619, 10 μg/ml pepstatin + leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 
5 mM N-ethylmaleimide) on ice or in co-IP assays, a milder lysis buffer was used by changing detergent to 0.4% 
NP-40. Reagents were from Sigma. Precipitates were isolated using magnetic beads (Dynabeads M-280, Ther-
moFisher Scientific). For detecting direct ubiquitination of MLC1 or GlialCAM, lysates were denatured using 
1% SDS for 5 min, after which the SDS concertation was adjusted to 0.1%. The second IP step was performed 
using anti-HA (Biolegends, CA, USA; for MLC1) or anti-GlialCAM (Santa Cruz, TX, USA and ThermoFisher 
Scientific). P4D1 (Santa Cruz, TX, USA) anti-ubiquitin Ab was used to detect ubiquitinated conjugates. Treat-
ment with cycloheximide (100 μg/ml, Sigma) was carried out in full medium at 37 °C for indicated times. BFA 
treatment (5 μg/ml, Sigma) was done in the full medium at 37 °C for 20 h. Proteasomes were inhibited using 
Bortezomib (1 μM, 4 h, LC Laboratories, MA, USA), lysosomes with leupeptin-pepstatin (1 μg/ml, o/n, Sigma) 
and autophagy with 3-methyladenine (5 μM, 4 h, Sigma). For all assays, polypeptides were separated using SDS-
PAGE and Western blot analysis. Densitometric analyses were done using Image Studio Lite (LiCOR) or Fiji 
(National Institutes of Health). When quantification was done for the IP samples, the signal was normalized to 
the amount of precipitated MLC1 or GliaCAM.
Metabolic pulse‑chase analyses. Metabolic pulse-chase experiments were performed essentially as 
 described46. Briefly, control and GlialAM overexpressing cells were pulse-labelled with 0.2 mCi/ml 5S-methio-
nine and 35S-cysteine (EasyTag Express Protein Labeling Mix, PerkinElmer) in cysteine and methionine-free 
medium for 20 min or 1 h at 26 °C (incorporation efficiency), and with 3 h chase at 37 °C (maturation effi-
ciency) when indicated. MLC1 was immunoprecipitated with an anti-HA antibody. Incorporated radioactivity 
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was visualized by fluorography and densitometric phosphorimager analysis using a Typhoon imaging platform 
(GE Healthcare).
Microscope imaging. For confocal colocalization microscopy (Leica TCS SP8X confocal microscope or 
LSM780 microscope, Carl Zeiss MicroImaging, 63 ×/1.4 NA Plan Apochromat oil-immersion objective) cells 
were cultured in 100  µg/ml poly-l-lysine-coated coverslips and fixed with 4% paraformaldehyde in PBS for 
15 min. Intracellular antigens were visualized in fixed, permeabilized cells using the indicated primary Abs in 
PBS-0.5% BSA for 1 h at room temperature. Primary antibodies were mouse anti-HA (Biolegends, CA, USA), 
rabbit anti-EEA1 (Cell Signalling, MA, USA), rabbit anti-calreticulin, mouse anti-LAMP2 (Developmentals 
studies hybridoma bank, IA, USA) and anti-LAMP1 (Abcam, Cambridge, UK). Secondary antibodies goat anti-
rabbit Alexa 488 and 594 were from ThermoFisher Scientific. Image analysis was performed using Fiji software.
To measure the lateral diffusional mobility of MLC1 at the PM, the FLIP experiment was performed using 
a confocal microscope. All imaging and bleaching were carried out using the 488-nm laser line. Following the 
acquisition of a baseline image, a region was selected for photobleaching. Time-series images were acquired 
from the adjacent area to photobleached one for monitoring loss in intensity. Typically, 3–6 intensity curves per 
experiment were collected and the final curve represented in figures are the averages of normalized intensities 
from at least three different experiments. The decay rates were analyzed using GraphPad Prism.
The high-content screening was performed using a widefield In Cell 2200 Imaging Analyzer equipped with 
an sCMOS camera and LED light source (GE Healthcare Life Sciences, USA; 60 ×/0.95 Plan Apo objective). 
Early endosomes were labelled with anti-EEA1 and late-endosomes, lysosomes anti-Lamp2 as above and nucleus 
using DRAQ5 (ThermoFisher Scientific). The nuclear stain was used to count an equal amount of cells (~ 300) 
from three experiments and image analysis was performed in In Cell Developer Toolbox (GE Healthcare Life 
Sciences, USA) by using a colocalization module to identify EAA1/Lamp2 positive endosomes with overlap 
coefficient and segmentation module to measure Lamp2 lysosome size and number. Statistical analysis was 
done in GraphPad Prism.
The pH of endo-lysosomal organelles was measured using live-cell single vesicle fluorescence ratio image 
analysis as described  previously5,28,37,38. The FITC-dextran (10 kDa, ThermoFisher Scientific) was loaded to live 
cells for 5 min at 37 °C, washed and the remaining label was chased for indicated times to measure the intralumi-
nal pH at the length of the endo-lysosomal pathway. Model membrane proteins (CD4tl-L57C and CD4tl-Ub)28 
were labelled sequentially with mouse anti-human CD4 (Biorad) and with FITC-goat anti-mouse secondary Fab 
(Jackson Immunoresearch) and allowed to continue for indicated times at 37 °C. Recycling endosomes were 
labelled with 5 µg/ml FITC-Tf (Jackson Immunoresearch) for 1 h. At least > 250 vesicles from 25–50 cells per 
experiment were analyzed, and the average weighted mean was calculated from the three or more independent 
experiments. The analysis was performed on an inverted fluorescence microscope Nikon TI-E equipped with 
Lumencor Spectra X light source and electron-multiplying charge-coupled device (Photometrics) equipped with 
an Evolve 512 electron-multiplying charge-coupled device (EM CCD) camera (Photometrics Technology) and 
a 63 ×/1.4 numerical aperture (NA) Plan Apochromat oil-immersion objective. The acquisition was performed 
at 490 ± 5- and 440 ± 10-nm excitation wavelengths using a 535 ± 25-nm emission filter and was analyzed with 
NIS-Elements (Nikon).
Recombinant protein production and GST pulldown assay. GST-GCAM expression in E. coli BL21 
was induced with 0.1 mM IPTG for 5 h at 30 °C, and bacteria was lysed in (100 mM Tris–HCl pH 7.5, 50 mM 
NaCl, 5 mM EDTA, 0.5% Triton X-100, 5% glycerol, 4 mM DTT, protease inhibitors and 1 mM PMSF) and affin-
ity purified on glutathione-Sepharose beads (GE Healthcare). Hela cell lysates (0.4 mg) expressing MLC1 mol-
ecules were used to detect interaction with the GlialCAM tail and GST alone was used as control. Glutathione-
Sepharose bound GST-GCAM was incubated with lysates for 2 h at 4 °C, beads were washed, and bound forms 
were analyzed using SDS-PAGE and Western blot analysis.
Statistical analysis. All data analysis was performed using GraphPad Prism 8.0–9.0 (San Diego, CA, USA). 
Paired or unpaired two-tailed Student’s t test was used for p-values as indicated in the figure legends. All data 
in curves and bar plots represent the means average of at least three or more independent experiments. Repeat 
numbers and parametric t test p-values for individual assays with comparison to Mann–Whitney test, when 
possible, can be found as Supplementary Table S1 online. Data are expressed as means ± SEM. ****p < 0.0001, 
***p < 0.001, **p < 0.01 and *p < 0.05.
Received: 27 May 2021; Accepted: 24 August 2021
References
 1. Case, L. B., Ditlev, J. A. & Rosen, M. K. Regulation of transmembrane signaling by phase separation. Annu. Rev. Biophys. 48, 
465–494 (2019).
 2. Dorrbaum, A. R., Kochen, L., Langer, J. D. & Schuman, E. M. Local and global influences on protein turnover in neurons and glia. 
Elife 7, e34202 (2018).
 3. Apaja, P. M. & Lukacs, G. L. Protein homeostasis at the plasma membrane. Physiology (Bethesda) 29, 265–277 (2014).




Scientific Reports |        (2021) 11:18435  | https://doi.org/10.1038/s41598-021-97777-4
www.nature.com/scientificreports/
 5. Apaja, P. M. et al. Ubiquitination-dependent quality control of hERG K+ channel with acquired and inherited conformational 
defect at the plasma membrane. Mol. Biol. Cell 24, 3787–3804 (2013).
 6. Foo, B. et al. Mutation-specific peripheral and ER quality control of hERG channel cell-surface expression. Sci. Rep. 9, 6066 (2019).
 7. Sontag, E. M., Samant, R. S. & Frydman, J. Mechanisms and functions of spatial protein quality control. Annu. Rev. Biochem. 86, 
97–122 (2017).
 8. Sun, Z. & Brodsky, J. L. Protein quality control in the secretory pathway. J. Cell Biol. 218, 3171–3187 (2019).
 9. Chung Moh, M., Hoon Lee, L. & Shen, S. Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule sup-
pressed in human hepatocellular carcinoma. J. Hepatol. 42, 833–841 (2005).
 10. Brignone, M. S. et al. MLC1 protein: A likely link between leukodystrophies and brain channelopathies. Front. Cell. Neurosci. 9, 
66 (2015).
 11. Capdevila-Nortes, X. et al. Insights into MLC pathogenesis: GlialCAM is an MLC1 chaperone required for proper activation of 
volume-regulated anion currents. Hum. Mol. Genet. 22, 4405–4416 (2013).
 12. Gaitan-Penas, H. et al. Leukoencephalopathy-causing CLCN2 mutations are associated with impaired Cl(–) channel function and 
trafficking. J. Physiol. 595, 6993–7008 (2017).
 13. Lanciotti, A. et al. Megalencephalic leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the TRPV4 
cation channel to activate the response of astrocytes to osmotic stress: Dysregulation by pathological mutations. Hum. Mol. Genet. 
21, 2166–2180 (2012).
 14. Brignone, M. S. et al. The beta1 subunit of the Na, K-ATPase pump interacts with megalencephalic leucoencephalopathy with 
subcortical cysts protein 1 (MLC1) in brain astrocytes: New insights into MLC pathogenesis. Hum. Mol. Genet. 20, 90–103 (2011).
 15. Hwang, J., Vu, H. M., Kim, M. S. & Lim, H. H. Plasma membrane localization of MLC1 regulates cellular morphology and motility. 
Mol. Brain 12, 116 (2019).
 16. Lattier, J. M. et al. Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in 
the brain microenvironment. Oncogene 39, 7253–7264 (2020).
 17. Elorza-Vidal, X. et al. GlialCAM/MLC1 modulates LRRC8/VRAC currents in an indirect manner: Implications for megalencephalic 
leukoencephalopathy. Neurobiol. Dis. 119, 88–99 (2018).
 18. Jeworutzki, E. et al. GlialCAM, a protein defective in a leukodystrophy, serves as a ClC-2 Cl(–) channel auxiliary subunit. Neuron 
73, 951–961 (2012).
 19. Duarri, A. et al. Knockdown of MLC1 in primary astrocytes causes cell vacuolation: A MLC disease cell model. Neurobiol. Dis. 
43, 228–238 (2011).
 20. van der Knaap, M. S., Abbink, T. E. M. & Min, R. Megalencephalic leukoencephalopathy with subcortical cysts. In GeneReviews((R)) 
(eds Adam, M. P. et al.) (University of Washington, 1993).
 21. Hamilton, E. M. C. et al. Megalencephalic leukoencephalopathy with subcortical cysts: Characterization of disease variants. 
Neurology 90, e1395–e1403 (2018).
 22. Bi, M. M. et al. Chloride channelopathies of ClC-2. Int. J. Mol. Sci. 15, 218–249 (2013).
 23. Rakers, C., Schmid, M. & Petzold, G. C. TRPV4 channels contribute to calcium transients in astrocytes and neurons during peri-
infarct depolarizations in a stroke model. Glia 65, 1550–1561 (2017).
 24. Hoegg-Beiler, M. B. et al. Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel 
dysfunction. Nat. Commun. 5, 3475 (2014).
 25. Lopez-Hernandez, T. et al. Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial 
macrocephaly, and macrocephaly with retardation and autism. Am. J. Hum. Genet. 88, 422–432 (2011).
 26. Lopez-Hernandez, T. et al. Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy 
with subcortical cysts. Hum. Mol. Genet. 20, 3266–3277 (2011).
 27. Capdevila-Nortes, X. et al. Structural determinants of interaction, trafficking and function in the ClC-2/MLC1 subunit GlialCAM 
involved in leukodystrophy. J. Physiol. 593, 4165–4180 (2015).
 28. Apaja, P. M., Xu, H. & Lukacs, G. L. Quality control for unfolded proteins at the plasma membrane. J. Cell Biol. 191, 553–570 
(2010).
 29. Okiyoneda, T. et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805–810 
(2010).
 30. Okiyoneda, T. et al. Chaperone-independent peripheral quality control of CFTR by RFFL E3 ligase. Dev. Cell 44, 694-708 e697 
(2018).
 31. van der Knaap, M. S., Boor, I. & Estevez, R. Megalencephalic leukoencephalopathy with subcortical cysts: Chronic white matter 
oedema due to a defect in brain ion and water homoeostasis. Lancet Neurol. 11, 973–985 (2012).
 32. Wang, B. B. et al. Ubr1-dependent selective autophagy (endo-phagy) alleviates membrane protein- and  Ca2+-induced proteotoxic 
endo-lysosomal stress (2021) (in submission).
 33. Beutel, O., Maraspini, R., Pombo-Garcia, K., Martin-Lemaitre, C. & Honigmann, A. Phase separation of zonula occludens proteins 
drives formation of tight junctions. Cell 179, 923-936 e911 (2019).
 34. Banjade, S. & Rosen, M. K. Phase transitions of multivalent proteins can promote clustering of membrane receptors. Elife 3, e04123 
(2014).
 35. Trimble, W. S. & Grinstein, S. Barriers to the free diffusion of proteins and lipids in the plasma membrane. J. Cell Biol. 208, 259–271 
(2015).
 36. de Araujo, M. E. G., Liebscher, G., Hess, M. W. & Huber, L. A. Lysosomal size matters. Traffic 21, 60–75 (2020).
 37. Barriere, H., Apaja, P., Okiyoneda, T. & Lukacs, G. L. Endocytic sorting of CFTR variants monitored by single-cell fluorescence 
ratiometric image analysis (FRIA) in living cells. Methods Mol. Biol. 741, 301–317 (2011).
 38. Kazan, J. M., Lukacs, G. L., Pause, A. & Apaja, P. M. Single cell fluorescence ratio image analysis for studying ESCRT function in 
receptor trafficking. Methods Mol. Biol. 1998, 93–103 (2019).
 39. Maxfield, F. R. & McGraw, T. E. Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5, 121–132 (2004).
 40. Estevez, R. et al. Megalencephalic leukoencephalopathy with subcortical cysts: A personal biochemical retrospective. Eur. J. Med. 
Genet. 61, 50–60 (2018).
 41. Lukacs, G. L. et al. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic 
reticulum and requires ATP. EMBO J. 13, 6076–6086 (1994).
 42. Meusser, B., Hirsch, C., Jarosch, E. & Sommer, T. ERAD: The long road to destruction. Nat. Cell Biol. 7, 766–772 (2005).
 43. Barriere, H., Nemes, C., Du, K. & Lukacs, G. L. Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endo-
somal sorting machinery. Mol. Biol. Cell 18, 3952–3965 (2007).
 44. Ingolia, N. T., Lareau, L. F. & Weissman, J. S. Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynam-
ics of mammalian proteomes. Cell 147, 789–802 (2011).
 45. Glozman, R. et al. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. 
J. Cell Biol. 184, 847–862 (2009).
 46. Veit, G. et al. Ribosomal stalk protein silencing partially corrects the DeltaF508-CFTR functional expression defect. PLoS Biol. 14, 
e1002462 (2016).
 47. Lanciotti, A. et al. Megalencephalic leukoencephalopathy with subcortical cysts disease-linked MLC1 protein favors gap-junction 
intercellular communication by regulating connexin 43 trafficking in astrocytes. Cells 9, 1425 (2020).
17
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18435  | https://doi.org/10.1038/s41598-021-97777-4
www.nature.com/scientificreports/
 48. Gilbert, A., Vidal, X. E., Estevez, R., Cohen-Salmon, M. & Boulay, A. C. Postnatal development of the astrocyte perivascular MLC1/
GlialCAM complex defines a temporal window for the gliovascular unit maturation. Brain Struct. Funct. 224, 1267–1278 (2019).
 49. Brignone, M. S. et al. Megalencephalic leukoencephalopathy with subcortical cysts protein-1 (MLC1) counteracts astrocyte activa-
tion in response to inflammatory signals. Mol. Neurobiol. 56, 8237–8254 (2019).
 50. Boor, I. et al. MLC1 is associated with the dystrophin–glycoprotein complex at astrocytic endfeet. Acta Neuropathol. 114, 403–410 
(2007).
 51. Horak, M., Petralia, R. S., Kaniakova, M. & Sans, N. ER to synapse trafficking of NMDA receptors. Front. Cell. Neurosci. 8, 394 
(2014).
 52. Keable, R., Leshchyns’ka, I. & Sytnyk, V. Trafficking and activity of glutamate and GABA receptors: Regulation by cell adhesion 
molecules. Neuroscientist 26, 415–437 (2020).
 53. Schmidt, N. et al. Neuroplastin and basigin are essential auxiliary subunits of plasma membrane Ca(2+)-ATPases and key regula-
tors of Ca(2+) clearance. Neuron 96, 827-838 e829 (2017).
 54. Natan, E., Wells, J. N., Teichmann, S. A. & Marsh, J. A. Regulation, evolution and consequences of cotranslational protein complex 
assembly. Curr. Opin. Struct. Biol. 42, 90–97 (2017).
 55. Elorza-Vidal, X. et al. Structural basis for the dominant or recessive character of GLIALCAM mutations found in leukodystrophies. 
Hum. Mol. Genet. 29, 1107–1120 (2020).
 56. Beesley, P., Kraus, M. & Parolaro, N. The neuroplastins: Multifunctional neuronal adhesion molecules—Involvement in behaviour 
and disease. Adv. Neurobiol. 8, 61–89 (2014).
 57. Wilson, M. C. et al. The neuroplastin adhesion molecules are accessory proteins that chaperone the monocarboxylate transporter 
MCT2 to the neuronal cell surface. PLoS One 8, e78654 (2013).
 58. Joutsen, J. et al. Heat shock factor 2 protects against proteotoxicity by maintaining cell–cell adhesion. Cell Rep. 30, 583-597 e586 
(2020).
 59. Kharitidi, D. et al. Interplay of endosomal ph and ligand occupancy in integrin alpha5beta1 ubiquitination, endocytic sorting, and 
cell migration. Cell Rep. 13, 599–609 (2015).
Acknowledgements
We thank Dr. Clair Brown (McGill University) for assistance with microscopy and the SAHMRI microscope 
facility.
Author contributions
Conceptualization: H.X., S.I., T.L.-H., R.E., G.L.L., P.M.A.; Methodology: H.X., S.I., T.L.-H., P.M.A.; Formal 
analysis: P.M.A.; Investigation: G.L.L., P.M.A.; Resources: R.E., G.L.L., P.M.A.; Writing-original draft: P.M.A.; 
Writing—review and editing: R.E., G.L.L., P.M.A.; Visualization: G.L.L., P.M.A.; Supervision: G.L.L., P.M.A.; 
Project administration: G.L.L., P.M.A.; Funding acquisition: G.L.L., P.M.A.
Funding
This work was supported by the E-Rare-CIHR/IRSC and EMBL Australia. P.M.A is an EMBL Australia Group 
Leader.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 97777-4.
Correspondence and requests for materials should be addressed to G.L.L. or P.M.A.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
